daunorubicin has been researched along with pci 32765 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abdul-Aziz, A; Bowles, KM; Lawes, M; MacEwan, DJ; Pillinger, G; Rushworth, SA; Zaitseva, L | 1 |
| Gronda, M; Hurren, R; Minden, MD; Rotin, LE; Schimmer, AD; Slassi, M; Wang, X | 1 |
2 other study(ies) available for daunorubicin and pci 32765
| Article | Year |
|---|---|
Targeting BTK for the treatment of FLT3-ITD mutated acute myeloid leukemia.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Apoptosis; Blast Crisis; Cell Line, Tumor; Cell Survival; Daunorubicin; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Mutation; Piperidines; Protein Structure, Tertiary; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines; RNA, Small Interfering; Signal Transduction | 2015 |
Investigating the synergistic mechanism between ibrutinib and daunorubicin in acute myeloid leukemia cells.
Topics: Adenine; Cytarabine; Daunorubicin; Leukemia, Myeloid, Acute; Piperidines; Pyrazoles; Pyrimidines | 2016 |